Literature DB >> 16247615

Efficacy of micafungin for the treatment of candidemia.

D Andes, N Safdar.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16247615     DOI： 10.1007/s10096-005-0025-7

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN： 0934-9723            Impact factor:   3.267


× No keyword cloud information.
  20 in total

Review 1.  Echinocandin antifungal drugs.

Authors:  David W Denning
Journal:  Lancet       Date:  2003-10-04       Impact factor: 79.321

2.  Subtherapeutic ocular penetration of caspofungin and associated treatment failure in Candida albicans endophthalmitis.

Authors:  G M Gauthier; T M Nork; R Prince; D Andes
Journal:  Clin Infect Dis       Date:  2005-06-28       Impact factor: 9.079

3.  Nosocomial candidemia in non-neutropenic patients at an Italian tertiary care hospital.

Authors:  R Luzzati; G Amalfitano; L Lazzarini; F Soldani; S Bellino; M Solbiati; M C Danzi; S Vento; G Todeschini; C Vivenza; E Concia
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2000-08       Impact factor: 3.267

4.  International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia.

Authors:  L Ostrosky-Zeichner; D Kontoyiannis; J Raffalli; K M Mullane; J Vazquez; E J Anaissie; J Lipton; P Jacobs; J H Jansen van Rensburg; J H Rex; W Lau; D Facklam; D N Buell
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-10       Impact factor: 3.267

5.  Attributable mortality of nosocomial candidemia, revisited.

Authors:  Olafur Gudlaugsson; Shane Gillespie; Kathleen Lee; Jeff Vande Berg; Jianfang Hu; Shawn Messer; Loreen Herwaldt; Michael Pfaller; Daniel Diekema
Journal:  Clin Infect Dis       Date:  2003-10-08       Impact factor: 9.079

6.  Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program.

Authors:  Rana A Hajjeh; Andre N Sofair; Lee H Harrison; G Marshall Lyon; Beth A Arthington-Skaggs; Sara A Mirza; Maureen Phelan; Juliette Morgan; Wendy Lee-Yang; Meral A Ciblak; Lynette E Benjamin; Laurie Thomson Sanza; Sharon Huie; Siew Fah Yeo; Mary E Brandt; David W Warnock
Journal:  J Clin Microbiol       Date:  2004-04       Impact factor: 5.948

7.  Voriconazole salvage treatment of invasive candidiasis.

Authors:  L Ostrosky-Zeichner; A M L Oude Lashof; B J Kullberg; J H Rex
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-10-17       Impact factor: 3.267

8.  Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States.

Authors:  Luis Ostrosky-Zeichner; John H Rex; Peter G Pappas; Richard J Hamill; Robert A Larsen; Harold W Horowitz; William G Powderly; Newton Hyslop; Carol A Kauffman; John Cleary; Julie E Mangino; Jeannette Lee
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

9.  Amphotericin B: time for a new "gold standard".

Authors:  Luis Ostrosky-Zeichner; Kieren A Marr; John H Rex; Stuart H Cohen
Journal:  Clin Infect Dis       Date:  2003-07-22       Impact factor: 9.079

10.  A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects.

Authors:  John H Rex; Peter G Pappas; Adolf W Karchmer; Jack Sobel; John E Edwards; Susan Hadley; Corstiaan Brass; Jose A Vazquez; Stanley W Chapman; Harold W Horowitz; Marcus Zervos; David McKinsey; Jeannette Lee; Timothy Babinchak; Robert W Bradsher; John D Cleary; David M Cohen; Larry Danziger; Mitchell Goldman; Jesse Goodman; Eileen Hilton; Newton E Hyslop; Daniel H Kett; Jon Lutz; Robert H Rubin; W Michael Scheld; Mindy Schuster; Bryan Simmons; David K Stein; Ronald G Washburn; Linda Mautner; Teng-Chiao Chu; Helene Panzer; Rebecca B Rosenstein; Jenia Booth
Journal:  Clin Infect Dis       Date:  2003-05-08       Impact factor: 9.079
View more
  4 in total

1.  In vitro interactions of micafungin with amphotericin B against clinical isolates of Candida spp.

Authors:  Carolina Serena; Marçal Mariné; Guillermo Quindós; Alfonso J Carrillo; J F Cano; F Javier Pastor; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2008-01-28       Impact factor: 5.191

2.  Global surveillance of in vitro activity of micafungin against Candida: a comparison with caspofungin by CLSI-recommended methods.

Authors:  M A Pfaller; L Boyken; R J Hollis; S A Messer; S Tendolkar; D J Diekema
Journal:  J Clin Microbiol       Date:  2006-10       Impact factor: 5.948

3.  In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance.

Authors:  M A Pfaller; L Boyken; R J Hollis; J Kroeger; S A Messer; S Tendolkar; D J Diekema
Journal:  J Clin Microbiol       Date:  2007-11-21       Impact factor: 5.948

4.  Cerebrospinal fluid and plasma (1-->3)-beta-D-glucan as surrogate markers for detection and monitoring of therapeutic response in experimental hematogenous Candida meningoencephalitis.

Authors:  Ruta Petraitiene; Vidmantas Petraitis; William W Hope; Diana Mickiene; Amy M Kelaher; Heidi A Murray; Christine Mya-San; Johanna E Hughes; Margaret P Cotton; John Bacher; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2008-09-08       Impact factor: 5.191
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.